Crucell Teams up with ACE BioSciences and Harvard to Accelerate Bacterial Antibody Program
Crucell intends to develop therapeutic antibodies against these targets to treat serious hospital-acquired infections, including those caused by antibiotic-resistant bacteria. In the US and Europe, hospital-acquired bacterial infections now affect about 2 million patients per year causing 200,000 deaths, and attributable costs amount to more than US$ 5 billion in the US alone.
"While vaccines against diseases like influenza, West Nile and malaria are successfully progressing towards Phase I clinical testing, we consider antibody products to be the next area to profit from the strength of the PER.C6® cell substrate platform," said Crucell's Chief Scientific Officer, Dr Jaap Goudsmit.
Crucell considers the rise in hospital-acquired infections caused by antibiotic-resistant bacteria to present opportunities for the development of alternative treatments to replace or complement antibiotics. Antibiotic-resistant bacteria increase the severity of disease, escalating mortality rates and driving up costs.
Most read news
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous